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Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia
patients with 11q deletion identifies a subgroup with very
aggressive disease
Chronic lymphocytic leukaemia (CLL) patients with the
11q22.3-q23.1 deletion (11q) show a less favourable outcome
(D€ohner et al, 2000); however, a certain degree of prognostic
heterogeneity within this subgroup has been recognised, with a
reported time to first treatment (TFT) ranging from 13 to
31 months (Guarini et al, 2012; Jeromin et al, 2014; Baliakas
et al, 2015). The minimal deleted region (MDR) on 11q always
includes ATM and can also encompass BIRC3, located on the
11q22.2 band, 6 Mb centromeric to ATM (Rose-Zerilli et al,
2014). BIRC3 inactivation by mutations and/or deletions has
been associated with a chemorefractory phenotype in patients
with wild-type (WT) TP53 (Rossi et al, 2012).
We aimed to: (i) screen BIRC3 disruption by copy num-
ber aberration (CNA) and mutation analysis; (ii) explore the
clinical significance of BIRC3 deletions and/or mutations
among 11q- CLL patients.
The study included 134 untreated CLL patients with 11q
detected by fluorescence in situ hybridisation (FISH). BIRC3
CNA analysis was performed by CytoScan HD array (Affy-
metrix, Santa Clara, CA) in a discovery cohort of 55 11q
CLL and by the QX200TM Droplet DigitalTM polymerase
chain reaction (ddPCR) system (Bio-Rad, Hercules, CA,
USA) in a validation cohort of 79 11q CLL (Table I). The
two cohorts showed similar age, gender, white blood cell
(WBC) count and a superimposable TFT (median: 144 vs.
183 months, P = 0144) and follow-up (median 494 vs.
438, P = 0361). Mutational analysis of BIRC3, TP53, SF3B1
and NOTCH1 was performed by Sanger sequencing in all
cases and of ATM by next generation sequencing in the 10
cases harbouring the BIRC3 biallelic lesion. TFT was assessed
to evaluate the clinical impact of the BIRC3 lesions, in order
to avoid the confounding effects of different treatments
(Supplementary Methods).
In the discovery cohort (n = 55), the 11q was detected
by FISH in 80% of nuclei (range 25–99%). CytoScan HD
array revealed a heterogeneous size of 11q (036–
6514 Mbp), mostly large lesions (>5 Mbp in 51 patients,
927%). The MDR, located in the 11q22.3 region, encom-
passed 4 genes (ACAT1, ATM, CUL5, NPAT). In 45/55 cases
(818%), the deleted region included the BIRC3 gene. Fifty-
one cases (927%) showed several additional CNAs (average
42, range 1–14/patient), mostly deletions, with gain 2p, del4
(p15.2), del4(q22.1), gain 8q and del19(p13.3) recurring in
≥3 cases (Table SI, Figure S1 and S2).
In the validation cohort (n = 79), FISH detected the 11q
in 67% of nuclei (range 10–97%). ddPCR confirmed the
ATM deletion in all cases and revealed the deletion of BIRC3
in 60/79 cases (759%) (sensitivity: 10% of deleted cells)
(Figure S3).
Overall, BIRC3 deletion was identified in 105/134 11q
patients (78%), in line with the literature (Rossi et al, 2012;
Rose-Zerilli et al, 2014). BIRC3 mutations (n = 15) occurred
in 10/134 cases (75%) (4 from the discovery, 6 from the val-
idation cohort), all BIRC3 deleted, resulting in a biallelic dis-
ruption of the gene.
TP53, NOTCH1 and SF3B1 mutations, all mutually exclu-
sive, were identified in 1/98 (1%), 11/117 (94%) and 7/78
(89%) evaluated cases, respectively (Figure S4).
Among the 10 patients with BIRC3 biallelic lesion, 1 har-
boured a SF3B1 mutation, 1 a NOTCH1 mutation and none
harboured a 17p-/TP53 mutation. ATM analysis revealed 3
subclonal mutations in 2 cases (Table SII). Clinical features
were as follows: 6 were males, 4 females, median age 60 years
(range 51–69), with an unmutated IGHV status in 7 cases; 3
were Binet stage C and 6 Binet B (one unknown), with a
median WBC count of 100 9 109/l (range 11–3028 9 109/
l). 11q/BIRC3del/BIRC3mut CLL patients had a signifi-
cantly higher WBC count at diagnosis than 11q/BIRC3del/
BIRC3WT or 11q/BIRC3WT/BIRC3WT cases (P < 00001),
with 8 cases showing WBC >100 9 109/l, including 3 with
>200 9 109/l. Moreover, a higher proportion of these
patients were stage C (P = 0025), although there was no
Table I. Clinical and biological characteristics of the 134 11q CLL
patients.
Gender (male/female) 103/31
Age, years (range) 63 (39–90)
White blood cell count 9109/l (range) 364 (6–3028)
Binet stage A/B/C/unknown 44/70/10/10
IGHV unmutated/mutated 103/28
% of 11q deletion by FISH (range) 72 (10–99)
11q deletion only (n) 54
11q deletion with 17p deletion (n) 3*
11q deletion with trisomy 12 (n) 6
11q deletion with 13q deletion (n) 71
*Cases with 17p deletion: 2 cases with BIRC3 deleted/WT and 1 case
with BIRC3 WT/WT.
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difference in age, gender, IGHV mutations, additional FISH
lesions, NOTCH1/SF3B1/TP53 mutations or median time
from diagnosis to sampling.
After a median follow-up of 47 months (range 1–236), 93/
127 evaluable patients received chemotherapy/chemoim-
munotherapy (median TFT 16 months, range 02–236).
BIRC3 deleted cases showed a TFT comparable with WT
patients. Conversely, the BIRC3 biallelic lesion was associated
with a significantly shorter TFT than BIRC3 deleted or WT
(median TFT 5 vs. 16 months, P < 0004) (Fig 1), also when
the 2 ATM mutated cases were excluded from the analysis
(P = 0036) (Figure S5).
By multivariate analysis, stage (P < 00001), WBC count
(P = 002) and biallelic BIRC3 lesion (P = 0005) were asso-
ciated with a short TFT, whilst gender, age, CD38, ZAP70
and IGHV status were not.
Thus, CLL patients with biallelic BIRC3 inactivation
showed a more aggressive disease with significantly lower
TFT compared to other 11q cases. The absence of enrich-
ment in mutations in the known CLL driver genes (i.e.
TP53, NOTCH1, SF3B1) and the same ratio of unmutated/
mutated IGHV genes compared to the other 11q cases,
reinforce the clinical impact of the BIRC3 biallelic lesion,
that holds true even after exclusion of the 2 patients with
subclonal ATM mutations.
The effect of the BIRC3 biallelic disruption on disease
kinetics (i.e. the high WBC count and the short TFT) is in
line with the function of the BIRC3 protein, because the
inactivation of the BIRC3 gene leads to the constitutive acti-
vation of the non-canonical NF-jB pathway (Rossi et al,
2012).
Clonal ATM mutations rather than BIRC3 deletion and/or
mutation have been associated with a worse outcome among
11q CLL patients treated with chemotherapy (Rose-Zerilli
et al, 2014). However, of 36 11q CLL patients, 14 had
ATM mutations, 32 BIRC3 deletions and only 2 BIRC3
mutation, thus, the prognostic impact of the BIRC3 biallelic
lesion could not be conclusively inferred.
We have previously reported the presence of BIRC3 muta-
tions in 27% of 11q chemo-refractory CLL patients (Mes-
sina et al, 2014) and the clonal expansion in the peripheral
blood at relapse of BIRC3 deletion derived from the lymph
node (Del Giudice et al, 2016). Thus, BIRC3 lesions could
have a role as a predictive marker in CLL treated with
chemoimmunotherapy (Diop et al, 2017). Future evaluations
will clarify whether BIRC3 abnormalities are useful, not only
to refine the prognostic stratification of 11q CLL patients,
but also to identify cases with a sub-optimal response to
novel mechanism-based compounds.
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Table SI. Recurrent CNA in the 55 11q CLL belonging
to the discovery cohort.
Table SII. BIRC3 and ATM mutations in 11q CLL
patients with BIRC3 biallelic lesions.
Figure S1. CNAs per chromosome.
Figure S2. Heat-map of recurrent CNAs in 11q CLL
belonging to discovery cohort.
Figure S3. 2-D fluorescence amplitude plots.
Figure S4. Heat-map of 11q CLL cases.
Figure S5. TFT of 125 11q CLL cases according to the
presence of BIRC3 deletion+mutation (BIRC3 del/mut,
n = 8), BIRC3 deletion only (BIRC3 del/WT, n = 88) or
none (BIRC3 WT/WT, n = 29). The 2 ATM mutated cases
were excluded from the analysis.
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